Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 20/20 | 0.85 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5339847 | 0.99 | CCR5 (0.86) | CCR5CXCR4CYP2C9 | |
| Hydrochloric Acid SCHEMBL6189974 | 0.96 | CCR5 (0.86) | CCR5CXCR4CYP2C9 | |
| SCHEMBL5349292 | 0.92 | CCR5 (1.00) | CCR5CXCR4CYP2C9 | |
| SCHEMBL13864780 | 0.92 | CCR5 (1.00) | CCR5CXCR4CYP2C9 | |
| SCHEMBL5354277 | 0.92 | CCR5 (1.00) | CCR5CXCR4 | |
| Hydrochloric Acid SCHEMBL5346488 | 0.92 | CCR5 (1.00) | CCR5CXCR4CYP2C9 | |
| Hydrochloric Acid SCHEMBL5612859 | 0.91 | CCR5 (1.00) | CCR5CXCR4CYP2C9 | |
| SCHEMBL14404478 | 0.91 | CCR5 (0.85) | CCR5CXCR4CYP2C9 | |
| Aplaviroc SCHEMBL15531476 | 0.89 | CCR5 (1.00) | CCR5CXCR4CYP2C9 | |
| Aplaviroc SCHEMBL4577106 | 0.89 | CCR5 (1.00) | CCR5CXCR4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262193-B2 | Triazaspiro[5.5]undecane derivative and pharmaceutical composition comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | claimed |
| EP-1619194-A2 | Triazaspiro[5.5]undecane derivatives and pharmaceutical composition comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-25 | — | — | EP | claimed |
| US-20050215557-A1 | Triazaspiro[5.5]undecane derivative and pharmaceutical composition comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2005-09-29 | — | — | US | claimed |
| US-20040082584-A1 | Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | claimed |
| EP-1378510-A1 | TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-01-07 | — | — | EP | claimed |
| US-7285552-B2 | Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient | ONO PHARMACEUTICALS CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-7262193-B2 | Triazaspiro[5.5]undecane derivative and pharmaceutical composition comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-7262193-B2 | Triazaspiro[5.5]undecane derivative and pharmaceutical composition comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-7053090-B2 | Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-30 | — | — | US | disclosed |
| EP-1619194-A2 | Triazaspiro[5.5]undecane derivatives and pharmaceutical composition comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-25 | — | — | EP | disclosed |
| US-20050215557-A1 | Triazaspiro[5.5]undecane derivative and pharmaceutical composition comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2005-09-29 | — | — | US | disclosed |
| EP-1438962-A1 | DRUGS COMPRISING COMBINATION OF TRIAZASPIRO 5,5 U NDECANE DERIVATIVE WITH CYTOCHROME P450 ISOZYME 3A4 INHIBITOR AND/OR P−GLYCOPROTEIN INHIBITOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-21 | — | — | EP | disclosed |
| US-20040082584-A1 | Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1378510-A1 | TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082584-A1 | Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient | ACKR3, CXCR5, CCL11 | CCR5 4/4885CXCR4 17/4885CYP2C9 642/4885 |
| US-20050215557-A1 | Triazaspiro[5.5]undecane derivative and pharmaceutical composition comprising the same as active ingredient | ACKR3, CCL11, CCR7 | CCR5 5/4885CXCR4 22/4885CYP2C9 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.